Petosemtamab for advanced head and neck cancer after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called petosemtamab for people with head and neck cancer that has gotten worse after immunotherapy and platinum chemotherapy. The goal is to see if it works better than the standard single-drug options available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your head and neck cancer must have spread or come back after standard treatments, including immunotherapy (anti-PD-1) and platinum chemotherapy.
- The cancer must be in the oropharynx, oral cavity, hypopharynx, or larynx (not nasopharynx).
- You need to be able to do daily activities without much help (ECOG 0 or 1).
- You must have measurable tumors on scans and a tumor sample available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
This Phase 1 study tests a new way to use a scan (PET/CT) with a drug called panitumumab to help spot where head and neck squamous cell cancer has spread. It may help doctors better target treatment by finding metastases earlier or more clearly.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.